294 related articles for article (PubMed ID: 19797607)
1. Inhibition of CYP3A by erythromycin: in vitro-in vivo correlation in rats.
Zhang X; Galinsky RE; Kimura RE; Quinney SK; Jones DR; Hall SD
Drug Metab Dispos; 2010 Jan; 38(1):61-72. PubMed ID: 19797607
[TBL] [Abstract][Full Text] [Related]
2. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
Yamano K; Yamamoto K; Katashima M; Kotaki H; Takedomi S; Matsuo H; Ohtani H; Sawada Y; Iga T
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):443-52. PubMed ID: 11259329
[TBL] [Abstract][Full Text] [Related]
3. Bioactivation of a novel 2-methylindole-containing dual chemoattractant receptor-homologous molecule expressed on T-helper type-2 cells/D-prostanoid receptor antagonist leads to mechanism-based CYP3A inactivation: glutathione adduct characterization and prediction of in vivo drug-drug interaction.
Wong SG; Fan PW; Subramanian R; Tonn GR; Henne KR; Johnson MG; Tadano Lohr M; Wong BK
Drug Metab Dispos; 2010 May; 38(5):841-50. PubMed ID: 20100816
[TBL] [Abstract][Full Text] [Related]
4. Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes.
Mao J; Johnson TR; Shen Z; Yamazaki S
Drug Metab Dispos; 2013 Feb; 41(2):343-52. PubMed ID: 23129213
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory Effect of Oxethazaine on Midazolam Metabolism in Rats.
Namba H; Nishimura Y; Kurata N; Iwase M; Hirai T; Kiuchi Y
Biol Pharm Bull; 2017; 40(9):1361-1365. PubMed ID: 28867721
[TBL] [Abstract][Full Text] [Related]
6. In vivo inhibition of CYP3A-mediated midazolam metabolism by anchusan in rats.
Saito Y; Nishimura Y; Kurata N; Iwase M; Aoki K; Yasuhara H
J Pharmacol Sci; 2011; 115(3):399-407. PubMed ID: 21358120
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of ketoconazole, cimetidine and erythromycin on hepatic CYP3A activities in cats.
Shah SS; Sasaki K; Hayashi Y; Motoyama S; Helmi AR; Khalil WF; Shimoda M
J Vet Med Sci; 2009 Sep; 71(9):1151-9. PubMed ID: 19801894
[TBL] [Abstract][Full Text] [Related]
8. In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A.
Polasek TM; Sadagopal JS; Elliot DJ; Miners JO
Eur J Clin Pharmacol; 2010 Mar; 66(3):275-83. PubMed ID: 20012430
[TBL] [Abstract][Full Text] [Related]
9. Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite.
Zhang X; Quinney SK; Gorski JC; Jones DR; Hall SD
Drug Metab Dispos; 2009 Aug; 37(8):1587-97. PubMed ID: 19420129
[TBL] [Abstract][Full Text] [Related]
10. Investigation of drug-drug interaction via mechanism-based inhibition of cytochrome P450 3A by macrolides in dexamethasone-treated female rats.
Kanazu T; Sato N; Kadono K; Touchi A; Takeda Y; Yamaguchi Y; Baba T
Biopharm Drug Dispos; 2012 May; 33(4):195-206. PubMed ID: 22447511
[TBL] [Abstract][Full Text] [Related]
11. In-vivo and in-vitro metabolic clearance of midazolam, a cytochrome P450 3A substrate, by the liver under normal and increased enzyme activity in rats.
Higashikawa F; Murakami T; Kaneda T; Takano M
J Pharm Pharmacol; 1999 Apr; 51(4):405-10. PubMed ID: 10385212
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effects of continuous ingestion of Schisandrin A on CYP3A in the rat.
Li WL; Xin HW; Su MW
Basic Clin Pharmacol Toxicol; 2012 Feb; 110(2):187-92. PubMed ID: 21895978
[TBL] [Abstract][Full Text] [Related]
13. Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin.
Quinney SK; Zhang X; Lucksiri A; Gorski JC; Li L; Hall SD
Drug Metab Dispos; 2010 Feb; 38(2):241-8. PubMed ID: 19884323
[TBL] [Abstract][Full Text] [Related]
14. Prediction of the effect of erythromycin, diltiazem, and their metabolites, alone and in combination, on CYP3A4 inhibition.
Zhang X; Jones DR; Hall SD
Drug Metab Dispos; 2009 Jan; 37(1):150-60. PubMed ID: 18854379
[TBL] [Abstract][Full Text] [Related]
15. Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate.
Polasek TM; Miners JO
Eur J Clin Pharmacol; 2006 Mar; 62(3):203-8. PubMed ID: 16416302
[TBL] [Abstract][Full Text] [Related]
16. Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. II: establishment and evaluation of dexamethasone-pretreated female rats.
Kanazu T; Yamaguchi Y; Okamura N; Baba T; Koike M
Xenobiotica; 2004 May; 34(5):403-13. PubMed ID: 15370957
[TBL] [Abstract][Full Text] [Related]
17. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes.
Ito K; Ogihara K; Kanamitsu S; Itoh T
Drug Metab Dispos; 2003 Jul; 31(7):945-54. PubMed ID: 12814973
[TBL] [Abstract][Full Text] [Related]
18. [A limited sampling strategy of phenotyping probe midazolam to predict inhibited activities of hepatic CYP3A in rats].
Zhu XH; Jiao JJ; Zhang CL; Lou JS; Liu CX
Yao Xue Xue Bao; 2008 Sep; 43(9):905-11. PubMed ID: 19048780
[TBL] [Abstract][Full Text] [Related]
19. Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: evaluation of cynomolgus monkeys as surrogates for humans.
Kanazu T; Yamaguchi Y; Okamura N; Baba T; Koike M
Xenobiotica; 2004 May; 34(5):391-402. PubMed ID: 15370956
[TBL] [Abstract][Full Text] [Related]
20. Conflicting alterations in hepatic expression of CYP3A and enzyme kinetics in rats exposed to 5-fluorouracil: relevance to pharmacokinetics of midazolam.
Fukuno S; Nagai K; Fujiike M; Sasaki Y; Konishi H
Xenobiotica; 2019 Dec; 49(12):1470-1477. PubMed ID: 30714842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]